Full TitleGOG 3011: 0403: FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor a-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Mirvetuximab soravtansine (IMGN853) is an investigational drug designed to kill cancer cells by binding to a protein on tumor cells called folate receptor alpha, and then releasing a cell-killing drug. In this study, researchers are comparing the effectiveness of mirvetuximab soravtansine with standard chemotherapy in women with ovarian, primary peritoneal, or fallopian tube cancer that has continued to grow despite platinum-containing chemotherapy and is positive for folate receptor alpha.
Women in this study will be randomly assigned to receive either mirvetuximab soravtansine or chemotherapy (paclitaxel, topotecan, and pegylated doxorubicin). All medications are given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have ovarian, primary peritoneal, or fallopian tube cancer that has continued to grow despite at least four cycles of platinum-containing chemotherapy and is positive for folate receptor alpha.
- Patients may not have had more than three prior regimens of treatment that included chemotherapy or immunotherapy.
- Patients should recover from the serious side effects of prior treatment before entering the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for women age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Jason Konner at 646-888-4219.